Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Xalost S in Glaucoma
NCT04164459Phase 4Unknown
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of latanoprost in primary open-angle glaucoma (POAG) and normal tension glaucoma (NTG) (3 arms), sponsored by Taejoon Pharmaceutical Co., Ltd. Primary endpoint: Corneal Staining Score at 12 weeks. Status: unknown.
02
Drugs
latanoprost
03
Conditions
primary open-angle glaucoma (POAG)normal tension glaucoma (NTG)
Beyond the preview
Go deeper on NCT04164459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164459.